Diabetes treatment trials and tribulations: Overcoming therapeutic inertia - On-demand webinar
You need to login to participate in this education.
This education is accredited: RACGP 3 CPD, ACRRM 2 CME PD.
How can we encourage our patients to reach and maintain optimal glycaemic control in type 2 diabetes (T2D)? Often we need to rationalise what’s not working to be able to choose solutions that will work.
Join international expert Prof Kamlesh Khunti and two local experts, A/Prof Marg McGill and Dr Gary Deed in an engaging, interactive, on-demand webinar experience – customised for you.
Our distinguished panel will provide you with the latest international and Australian recommendations, in a case-based setting, to help you and your patients recognise and take steps to overcome this tricky issue!
By completing this learning activity, participants will be able to:
- Discuss the positive effect of early glycaemic control on patient outcomes in diabetes.
- Identify the causes of therapeutic inertia in diabetes management.
- Rationalise the phases and characteristics of insulin inertia, including initiation, titration and intensification.
- Apply practical, evidence-based strategies to overcome therapeutic inertia in the Australian primary practice setting, including the role of new generation, co-formulation insulins.
Accredited 1.5 ADEA CPD points
Accreditation ends Sept 2020
This activity is sponsored by Novo Nordisk.
|Diabetes treatment trials and tribulations: Overcoming therapeutic inertia - Education|
|Diabetes treatment trials and tribulations: Overcoming therapeutic inertia - Evaluation|